Til innhold

PHARMAQ Norway Transparency Act Statement 2023

Text module

This Statement describes the activities of Pharmaq AS and Pharmaq Analytiq AS (collectively "Pharmaq Norway," "we," "us" and "our") to address fundamental human rights and decent working conditions in our business and supply chain during the year ended December 31, 2023. This Statement is published pursuant to the "Act relating to enterprises' transparency and work on fundamental human rights and decent working conditions" (the "Transparency Act"). 

Section 1: a general description of the enterprise's structure, area of oper­ations, guidelines and procedures for handling actual and potential adverse impacts on fundamental human rights and decent working conditions. 

A. Structure and Area of Operations
Pharmaq Norway is an indirect wholly owned subsidiary of Zoetis Inc. ("Zoetis"). Zoetis is a global leader in the animal health industry, focused on the discovery, development, manufacture and commercialization of medicines, vaccines, diagnostic products and services, biodevices, genetic tests and precision animal health. Zoetis has a diversified business, marketing products across eight core species: dogs, cats, and horses (collectively, companion animals) and cattle, swine, poultry, fish, and sheep (collectively, livestock); and within eight major product categories: parasiticides, vaccines, dermatology, anti-infectives, pain and sedation, other pharmaceutical, animal health diagnostics and medicated feed additives. Zoetis' commitment to enhancing the health and quality of life of the communities in which we live and work is grounded in the belief that everyone should be treated fairly and with respect. 
Pharmaq Norway develops, manufactures, sells, and distributes vaccines and other fish health products to 
the global aquaculture industry, as well as providing targeted research and effective analyses with the aim of safeguarding fish health and welfare in the aquaculture sector through real-time qPCR, histopathology, and microbiology services. The main markets for Pharmaq Norway are the salmon and trout farming industries in Norway and the Nordics, Chile, Scotland, and Canada. Pharmaq Norway also has an important role as a supplier of fish health products to the sea bass industry in the Mediterranean region, the tilapia industry in Latin America, and the pangasius industry in Asia. 

Read more here.